In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-02-01
DOI
10.1093/jac/dkaa053
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
- (2019) Chau-Chyun Sheu et al. Frontiers in Microbiology
- Interplay between β-lactamases and new β-lactamase inhibitors
- (2019) Karen Bush et al. NATURE REVIEWS MICROBIOLOGY
- NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings
- (2019) Wenjing Wu et al. CLINICAL MICROBIOLOGY REVIEWS
- Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018
- (2019) Kati Räisänen et al. Eurosurveillance
- β-Lactamases and β-Lactamase Inhibitors in the 21st Century
- (2019) Catherine L. Tooke et al. JOURNAL OF MOLECULAR BIOLOGY
- Susceptibilities of Gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections: a 2016–2017 update of the Chinese SMART study
- (2019) Hui Zhang et al. Infection and Drug Resistance
- Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases
- (2019) Alen Krajnc et al. JOURNAL OF MEDICINAL CHEMISTRY
- VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
- (2019) Jodie C. Hamrick et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis
- (2018) Han Zhong et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
- (2017) Pablo A Fraile-Ribot et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Therapeutic options for carbapenem-resistant Enterobacteriaceae infections
- (2017) Enrico Maria Trecarichi et al. Virulence
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
- (2016) Ryan K. Shields et al. CLINICAL INFECTIOUS DISEASES
- An update on the management of urinary tract infections in the era of antimicrobial resistance
- (2016) Mazen S Bader et al. POSTGRADUATE MEDICINE
- β-Lactams and β-Lactamase Inhibitors: An Overview
- (2016) Karen Bush et al. Cold Spring Harbor Perspectives in Medicine
- Characterization ofEscherichia coliNDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3
- (2015) Richard A. Alm et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Multiplex PCR for detection of acquired carbapenemase genes
- (2011) Laurent Poirel et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Emergence of NDM-1-producing Acinetobacter baumannii in China
- (2011) Y. Chen et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started